Dr Henry Worth Parker, MD | |
1 Medical Center Dr, Lebanon, NH 03756-1000 | |
(603) 650-5131 | |
(603) 650-0580 |
Full Name | Dr Henry Worth Parker |
---|---|
Gender | Male |
Speciality | Internal Medicine - Pulmonary Disease |
Location | 1 Medical Center Dr, Lebanon, New Hampshire |
Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1346356367 | NPI | - | NPPES |
00000141 | Medicaid | NH | |
1000746 | Medicaid | VT |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207RP1001X | Internal Medicine - Pulmonary Disease | 6289 (New Hampshire) | Primary |
Mailing Address | Practice Location Address |
---|---|
Dr Henry Worth Parker, MD 1 Medical Center Dr, Lebanon, NH 03756-1000 Ph: (603) 650-5131 | Dr Henry Worth Parker, MD 1 Medical Center Dr, Lebanon, NH 03756-1000 Ph: (603) 650-5131 |
News Archive
LifeWatch AG, a leading developer and provider of medical solutions and remote diagnostic monitoring services in the digital health market, is pleased to announce that it has received FDA clearance for its continuous Vital Signs Monitoring Service.
The blood vessels of obese children have stiffness normally seen in much older adults with cardiovascular disease, Dr. Kevin Harris today told the Canadian Cardiovascular Congress 2010, co-hosted by the Canadian Cardiovascular Society and the Heart and Stroke Foundation. The clock is ticking and the shape of the 13 year-old-heart is changing - for the worse.
Climbing suicide rates over the past ten years have prompted three Joint Commission Sentinel Event Alerts - the most recent in February 2016 - urging health care organizations to step up screening and detection of those individuals most at risk. But due to a shortage of both time and psychiatry staff, complying with this mandate presents a challenge.
Ranbaxy Pharmaceuticals Inc., a wholly owned subsidiary of Ranbaxy Laboratories Ltd. (RLL), has launched authorized generic pioglitazone hydrochloride tablets in the U.S. market, under an agreement with Takeda Pharmaceuticals U.S.A., Inc.
Administration of a bolus dose of the anticoagulant drug abciximab into the coronary artery involved in causing a certain type of heart attack among patients who were undergoing a percutaneous coronary intervention and also receiving another anticoagulant resulted in reduction in the size of damage to the heart muscle at 30 days, while a procedure that involved use of a catheter to remove the blood clot blocking that coronary artery did not produce these results, according to a study appearing in JAMA.
› Verified 3 days ago
Elias Loukas, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 1 Medical Center Dr, Dhmc Section Of Hospital Medicine, Lebanon, NH 03756 Phone: 603-650-8380 | |
Dr. Michael W Winter, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: One Medical Center Drive, Gastroenterology, Lebanon, NH 03756 Phone: 603-650-5261 | |
Hannah Elizabeth Foote Bensimhon, M.D. Pulmonary Disease Medicare: Medicare Enrolled Practice Location: 1 Medical Center Dr, Lebanon, NH 03756 Phone: 603-650-5000 | |
Victoria Forbes, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 1 Medical Center Dr, Lebanon, NH 03756 Phone: 603-650-5516 | |
Zanira Fazal, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 18 Old Etna Rd, Lebanon, NH 03766 Phone: 603-650-4000 | |
Susan Si-yao Wang, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 1 Medical Center Dr, Dartmouth-hitchcock Medical Ctr, Department Of Medicine, Lebanon, NH 03756 Phone: 603-650-9480 | |
Mark Edward Splaine, MD Pulmonary Disease Medicare: Not Enrolled in Medicare Practice Location: 1 Medical Center Dr, Dhmc Section Of General Internal Medicine, Lebanon, NH 03756 Phone: 603-653-9500 |